TY - JOUR
TI - Chemotherapy and targeted treatments of breast sarcoma by histologic subtype
AU - Kokkali, S.
AU - Stravodimou, A.
AU - Duran-Moreno, J.
AU - Koufopoulos, N.
AU - Voutsadakis, I.A.
AU - Digklia, A.
JO - Expert Review of Anticancer Therapy
PY - 2021
VL - 21
TODO - 6
SP - 591-604
PB - Taylor and Francis Ltd.
SN - 1473-7140, 1744-8328
TODO - 10.1080/14737140.2021.1880327
TODO - antineoplastic agent;  bevacizumab;  doxorubicin;  durvalumab;  eribulin;  gemcitabine;  ifosfamide;  olaratumab;  pembolizumab;  platelet derived growth factor receptor;  protein tyrosine kinase inhibitor;  regorafenib;  sarc 028;  trabectedin;  unclassified drug;  vasculotropin receptor, advanced cancer;  angiosarcoma;  breast sarcoma;  cancer chemotherapy;  cancer diagnosis;  cancer immunotherapy;  cancer staging;  cancer surgery;  cancer therapy;  chondrosarcoma;  clinical feature;  dermatofibrosarcoma protuberans;  early cancer;  fibrosarcoma;  histology;  human;  Kaposi sarcoma;  leiomyosarcoma;  liposarcoma;  malignant fibrous histiocytoma;  mastectomy;  molecular pathology;  osteosarcoma;  patient care;  phyllodes tumor;  primary health care;  Review;  breast tumor;  female;  pathology;  sarcoma;  soft tissue tumor, Breast Neoplasms;  Female;  Humans;  Sarcoma;  Soft Tissue Neoplasms
TODO - Introduction: Breast sarcomas (BS) are uncommon and often present both diagnostic and therapeutic challenges. Historically, radical surgery has been the mainstay of treatment for localized breast sarcomas. On the other hand, in advanced disease, since they are a heterogeneous group of neoplasms consisting of several different subtypes including angiosarcoma, phyllodes tumor, and pleomorphic undifferentiated sarcoma, there is a lack of proven specific therapy. As a result, their treatment is based on the soft tissue sarcoma (STS) paradigm, whereas histotype-tailored approaches apply to specific subtypes like dermatofibrosarcoma protuberans. To date, advanced stages constitute an incurable form of disease and chemotherapy remains the cornerstone of treatment with the aim of palliation of symptoms and increase in survival. Areas covered: In this manuscript, we review the clinicopathologic characteristics of the most common subtypes of BS, as well as the current treatment landscape of BS, with a particular focus on opportunities and challenges provided by new targeted molecules and immunotherapy. Expert opinion: The treatment approach of advanced BS is based on the pathologic subtype. A true breakthrough has still to be obtained, as the development of new agents in BS suffers from the same weaknesses as in other STS. © 2021 Informa UK Limited, trading as Taylor & Francis Group.
ER -